Four States Petition FDA to Remove REMS Restrictions on Abortion Pill Mifepristone

Four states have formally requested the Food and Drug Administration (FDA) to remove specific restrictions placed on the abortion pill mifepristone. Officials from California, Oregon, Washington, and New York submitted a petition urging the agency to reevaluate its current regulations surrounding the medication. The request highlights extensive research that these states claim demonstrates the pill’s safety and efficacy.

The petition calls for an end to special requirements under the FDA’s Risk Evaluation and Mitigation Strategy (REMS), which imposes additional controls on how mifepristone is prescribed and dispensed. These measures include limiting distribution to certified healthcare providers in certain settings, such as clinics or hospitals, rather than pharmacies. The states argue that these restrictions are outdated and not supported by scientific evidence. They cite studies indicating that mifepristone has been safely used by millions of individuals since its approval in 2000 for medical abortions during early pregnancy. The FDA has yet to respond publicly to the petition or indicate whether it will review its policies regarding the drug.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: June 5, 2025

Related posts:

Medicare Trust Fund Shows Stability as HHS Restructures Amidst Anticipation of Advantage Rate Announcement 12th Outsourcing in Clinical Trials UK & Ireland Conference to Focus on Positioning the UK as a Global Leader in Medical Research Spencer Jones Discusses December 2023 Trends in Digital Health and Personalized Medicine FDA Panel Rejects Expanded Use of Pfizer’s Talzenna for Prostate Cancer as AI Gains Attention in Clinical Trial Diversity

Author

Mark Chiang